Moreover, the unique capacity of rucaparib to inhibit STAT3 phosphorylation in MDA-MD-231 and MDA-MB-468 human breast cancer cell lines has been previously reported at concentrations below 2.5 μM, but this was not observed in response to olaparib25. This evidence concerns the gene STAT3 and breast carcinoma.